Moxi 400

Moxifloxacin HCl

Acute sinusitis & exacerbation of chronic bronchitis. Community-acquired pneumonia. Mild to moderately severe pelvic inflammatory disease. Complicated skin, skin structure & intra-abdominal infections.

Adult 1 tab once daily.

May be taken with or without food.

Hypersensitivity to moxifloxacin or other quinolones. Pregnacy & lactation. Patients <18 yr.

Hypersensitivity. Discontinue use if life-threatening shock occurs. QT interval prolongation; increased risk for ventricular arrhythmias including Torsade de pointes. Myasthenia gravis; uncorrected hypokalemia; ongoing proarrhythmic conditions eg, clinically significant bradycardia, acute myocardial ischemia. Known or suspected CNS disorders predisposing to seizures or lowered seizure threshold. Risk of developing fluoroquinolone-associated tendonitis & tendon rupture; complicated pelvic inflammatory disease. Heart & lung transplant recipients. Patients receiving class IA (eg, quinidine, procainamide) or class III (eg, amiodarone, sotalol) antiarrhythmics. Concomitant use w/ drugs prolonging QT interval eg, cisapride, erythromycin, antipsychotics, TCAs; corticosteroids. Patients on controlled Na diet. Fulminant hepatitis potentially leading to hepatic failure. Hepatic cirrhosis. Renal transplant recipients. Elderly >60 yr.

Mycotic superinfections; headache, dizziness; QT prolongation in patients w/ hypokalaemia; nausea, vomiting, GI & abdominal pains; diarrhea; increased transaminases; inj & infusion site reactions; increased γ-glutamyl transferase.

Impaired absorption w/ antacids, minerals, multivit, antiretroviral drugs eg, didasonine, other Mg- & Al-containing prep, sucralfate & Fe- or Zn-containing agents. Increased anticoagulant activity. Increased C_max of digoxin. Reduced systemic availability w/ charcoal.

Quinolones

J01MA14 - moxifloxacin ; Belongs to the class of fluoroquinolones. Used in the systemic treatment of infections.

B